You searched for: gonorrhoeae (Maltesiska - Engelska)

neisseria gonorrhoeae
neisseria gonorrhoeae neisseria meningitidis non-species-related breakpoints *

n. gonorrhoeae anaerobi
n. gonorrhoeae anaerobes

n. gonorrhoeae ie (evidenza insuffiċjenti)
n. gonorrhoeae ie (insufficient evidence)

l-iżolament tal-neisseria gonorrhoeae minn kampjun klinika
isolation of neisseria gonorrhoeae from a clinical specimen

- mard pelviku infjammatorju inklużi każijiet minħabba neisseria gonorrhoeae
- pelvic inflammatory disease including cases due to neisseria gonorrhoeae

- epididimo- orkite inklużi każijiet minħabba neisseria gonorrhoeae
- epididymo-orchitis including cases due to neisseria gonorrhoeae

marda infjammatorja tal- pelvi inkluż każijiet ikkawżati minn neisseria gonorrhoeae
epididymo-orchitis including cases due to neisseria gonorrhoeae

sejbien ta' n. gonorrhoeae l-antiġenu jew ta' l-aċidu nuklejku
detection of n. gonorrhoeae antigen or nucleic acid

- marda infjammatorja tal- pelvi tista ’ tkun ikkawżata minn neisseria gonorrhoeae reżistenti għal
- pelvic inflammatory disease may be caused by fluoroquinolone resistant neisseria

ciprofloxacin għandu jingħata flimkien ma ’ sustanza xierqa oħra kontra l- batterja sakemm neisseria gonorrhoeae reżistenti għal ciprofloxacin tista ’ tkun eskluda.
ciprofloxacin should be co-administered with another appropriate antibacterial agent unless ciprofloxacin-resistant neisseria gonorrhoeae can be excluded.

169 klebsiella oxytoca klebsiella pneumoniae * morganella morganii * neisseria gonorrhoeae * proteus mirabilis * proteus vulgaris * providencia spp.
164 aerobic gram-negative micro-organisms acinetobacter baumannii+ burkholderia cepacia+* campylobacter spp. +* citrobacter freundii* enterobacter aerogenes enterobacter cloacae* escherichia coli* klebsiella oxytoca klebsiella pneumoniae* morganella morganii* neisseria gonorrhoeae * proteus mirabilis* proteus vulgaris* providencia spp.

6 is- chmp ikkunsidra li minħabba t- tkattir ta ’ razez ta ’ n. gonorrhoeae reżistenti għal fluoroquinolone, moxifloxacin ma għandux jintuża fil- monoterapija empirika tal- pid ħafifa jew moderata, sakemm ma tkunx tista ’ tiġi eskluża reżistenza għal kontra moxifloxacin.
6 the chmp considered that due to the emergence of fluoroquinolone-resistant n. gonorrhoeae strains moxifloxacin should not be used in empirical monotherapy of mild to moderate pid, unless a resistance against moxifloxacin can be ruled out.